Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total transaction of $97,080.00. Following the sale, the general counsel now owns 105,386 shares in the company, valued at approximately $1,705,145.48. The trade was a 5.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 5.3 %

Shares of CNTA stock opened at $16.75 on Friday. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $16.71 and its 200 day moving average is $15.79. The stock has a market capitalization of $2.21 billion, a P/E ratio of -10.95 and a beta of 1.53.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the period. Barclays PLC grew its position in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the period. Finally, BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $162,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

CNTA has been the topic of a number of recent analyst reports. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.